key: cord-0744252-3ttry6bd authors: Subasinghe, Asvini K.; Mogharbel, Carolyn; Hill, Dianne; Mazza, Danielle title: Changes in women’s health service seeking behaviours and the impact of telehealth during COVID‐19: Insights from the 1800MyOptions service date: 2021-10-16 journal: Aust N Z J Obstet Gynaecol DOI: 10.1111/ajo.13409 sha: dc955a57028c0f2f1b3a6b0abbc9e5c9bb5b6697 doc_id: 744252 cord_uid: 3ttry6bd nan The COVID-19 pandemic has led to increased demand for pregnancy options counselling, more women presenting at later gestation and increased referrals for telehealth early medical abortions. Evidence for this is provided by changes to the number and nature of calls to the Victorian-based 1800MyOptions a government funded telephone information service, operated by Women's Health Victoria, about contraception, pregnancy options and sexual health. 1 We undertook an audit of de-identified data routinely collected by this service between March and July 2020. The nature of services requested, the gestation of pregnant callers and the major concerns of callers in relation to accessing sexual and reproductive health (SRH) services are recorded using standardised forms. All callers are aware that any data collected will be used for reporting purposes, but that no identifiable information is stored. Between March and July 2020, there was a significant increase in demand for pregnancy options counselling (n = 26/385, 7%), after an initial drop in March (n = 6/365, 1.6%, P < 0.001). More women were exploring their options at 18+ weeks gestation than prior to COVID-19 with an increase from 2.5% in March 2020 (9/365) to 8.8% in July 2020 (25/283, P < 0.001). Women described COVID-19 related factors impacting their decision making in the form of loss of employment, increased responsibilities associated with home schooling and feeling nervous about seeking health care. Comparing data between calls received between March and August 1800MyOptions referrals to telehealth abortion providers, for callers under nine weeks gestation, increased to 6.9% (n = 99/1429) between March and August in 2020 as compared to 4.1% These 1800MyOptions data provide evidence of increased demand for pregnancy counselling, increased presentation at later gestation and increased demand for virtual SRH consultations. These data highlight the impact of the pandemic on women's SRH and the ability of telehealth to respond to women's needs. Telehealth provision of essential SRH services can play a large role in achieving equitable SRH service provision for all Australian women, particularly those belonging to vulnerable groups 5 and should therefore continue to be supported. We read the recent article by Hsiao et al. with interest, regarding denial of medications for severe nausea and vomiting of pregnancy (NVP) or hyperemesis gravidarum (HG). 1 On reviewing the references required by community pharmacists, we found the information on doxylamine to be inconsistent and conflicting. Board of Australia's list of essential reference texts and pharmacists reviewing the suitability of doxylamine for NVP/HG would likely use a general reference from this list, namely, the Australian product information (PI), Australian Medicines Handbook (AMH), We reviewed the pregnancy safety information for doxylamine using these four essential references. The Australian PI (produced by the manufacturer) for Therapeutic Goods Association (TGA) registered medicines can be accessed through multiple sources, such as via the TGA's Australian Register of Therapeutic Goods (ARTG), or via paid subscriptions to online databases such as MIMS or AusDI. We found that the availability and the advice contained within the PI to be inconsistent across sources. Accessing the manufacturer's PI via the ARTG, MIMS or AusDI yielded differing recommendations regarding the safety of doxylamine in pregnancy. There were 21 registered doxylamine products listed on the ARTG, without the corresponding PI, whereas MIMS and AusDI listed eight brands, all with the appropriate accompanying PI (Table 1) . Information on the safety of doxylamine in pregnancy varied between sources of PI. There was also inconsistency between key sections within the PI itself (ie, Pregnancy Category and Use in Pregnancy) for most brands. Three brands stated that doxylamine could be used during pregnancy when considered essential under medical practitioner advice. The PI for five brands made no recommendation for use in pregnancy. 2,3 The inconsistent information between and within the manufacturer's PI may lead to confusion. The current APF does not contain specific information on individual drugs in pregnancy so is not helpful in this context. 6 The AMH states doxylamine is safe to use in its product monograph; noting that older antihistamines have been used extensively without adverse effects in the fetus. 5 The eTG Complete contains recommendations for NVP/HG with the first line agent listed as doxylamine. 7 The PI provided by the pharmaceutical manufacturer is known to be conservative, and at times misleading in comparison to independent resources. 9 There have been multiple calls to improve pregnancy data contained in the PI (such as details of fetal risk). 9,10 If pharmacists use the PI as their sole source of information, they may arrive at an incomplete or incorrect conclusion regarding the safety of doxylamine in pregnancy. Pregnancy safety information should be clear and consistent across different brands of the same medication. In the meantime, pharmacists should consult specialist pregnancy references such as The Women's Pregnancy and Breastfeeding Women's Health Victoria. 1800myoptions Telehealth changes improve remote Australians' access to a doctor 2019. Australia; Australian Government Department of Health Paying for telemedicine after the pandemic Women's SRH COVID-19 Coalition. A consensus statement on publicly funded abortion service provision: a duty of care. SPHERE National Health and Medical Research Council's Centre of Research Excellence in Women's SRH in Primary Care Women's SRH COVID-19 Coalition. Evidence-based practice and policy recommendations regarding early medical abortion: a consensus statement. SPHERE National Health and Medical Research Council's Centre of Research Excellence in Women's SRH in Primary Care